Literature DB >> 33552016

The Cyclic Oligoadenylate Signaling Pathway of Type III CRISPR-Cas Systems.

Fengtao Huang1, Bin Zhu1.   

Abstract

Type III CRISPR-Cas systems, which are widespread in both bacteria and archaea, provide immunity against DNA viruses and plasmids in a transcription-dependent manner. Since an unprecedented cyclic oligoadenylate (cOA) signaling pathway was discovered in type III systems in 2017, the cOA signaling has been extensively studied in recent 3 years, which has expanded our understanding of type III systems immune defense and also its counteraction by viruses. In this review, we summarized recent advances in cOA synthesis, cOA-activated effector protein, cOA signaling-mediated immunoprotection, and cOA signaling inhibition, and highlighted the crosstalk between cOA signaling and other cyclic oligonucleotide-mediated immunity discovered very recently.
Copyright © 2021 Huang and Zhu.

Entities:  

Keywords:  CARF domain proteins; CD-NTase; CRISPR immune defense; Cas10; cyclic oligonucleotide; type III systems

Year:  2021        PMID: 33552016      PMCID: PMC7854544          DOI: 10.3389/fmicb.2020.602789

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  67 in total

1.  Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition.

Authors:  Migle Kazlauskiene; Gintautas Tamulaitis; Georgij Kostiuk; Česlovas Venclovas; Virginijus Siksnys
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

2.  A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.

Authors:  Wenyuan Han; Stefano Stella; Yan Zhang; Tong Guo; Karolina Sulek; Li Peng-Lundgren; Guillermo Montoya; Qunxin She
Journal:  Nucleic Acids Res       Date:  2018-11-02       Impact factor: 16.971

3.  Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA4.

Authors:  Sharidan Brown; Colin C Gauvin; Alexander A Charbonneau; Nathaniel Burman; C Martin Lawrence
Journal:  J Biol Chem       Date:  2020-08-21       Impact factor: 5.157

Review 4.  Three New Cs for CRISPR: Collateral, Communicate, Cooperate.

Authors:  Andrew Varble; Luciano A Marraffini
Journal:  Trends Genet       Date:  2019-04-27       Impact factor: 11.639

5.  Degradation of Phage Transcripts by CRISPR-Associated RNases Enables Type III CRISPR-Cas Immunity.

Authors:  Wenyan Jiang; Poulami Samai; Luciano A Marraffini
Journal:  Cell       Date:  2016-02-04       Impact factor: 41.582

6.  Hybrid promiscuous (Hypr) GGDEF enzymes produce cyclic AMP-GMP (3', 3'-cGAMP).

Authors:  Zachary F Hallberg; Xin C Wang; Todd A Wright; Beiyan Nan; Omer Ad; Jongchan Yeo; Ming C Hammond
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-02       Impact factor: 11.205

7.  The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.

Authors:  Kawanda Foster; Joshua Kalter; Walter Woodside; Rebecca M Terns; Michael P Terns
Journal:  RNA Biol       Date:  2018-08-01       Impact factor: 4.652

8.  RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex.

Authors:  Michael A Estrella; Fang-Ting Kuo; Scott Bailey
Journal:  Genes Dev       Date:  2016-02-04       Impact factor: 11.361

9.  Comprehensive search for accessory proteins encoded with archaeal and bacterial type III CRISPR-cas gene cassettes reveals 39 new cas gene families.

Authors:  Shiraz A Shah; Omer S Alkhnbashi; Juliane Behler; Wenyuan Han; Qunxin She; Wolfgang R Hess; Roger A Garrett; Rolf Backofen
Journal:  RNA Biol       Date:  2018-06-19       Impact factor: 4.652

10.  Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.

Authors:  Kawanda Foster; Sabine Grüschow; Scott Bailey; Malcolm F White; Michael P Terns
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

View more
  1 in total

Review 1.  Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications.

Authors:  Yue-Ying Huang; Xiao-Yu Zhang; Ping Zhu; Ling Ji
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.